---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-025050"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2026-06-12T18:20:32+00:00"
generated_at: "2026-06-12T18:21:09.449620+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ionis olezarsen OLE data: liver fat returns toward baseline after 24 months; 90%+ retention

## Summary
- Mean hepatic fat fraction (HFF) levels returned toward baseline after 24 months of olezarsen 80 mg in CORE-OLE study of severe hypertriglyceridemia.
- Patients transitioning from 50 mg to 80 mg showed less pronounced HFF changes; safety profile remained favorable with longer treatment.
- Over 90% of eligible patients from CORE/CORE2 studies enrolled and remained in the open-label extension.
- Data presented at National Lipid Association Scientific Sessions in Chicago on June 12, 2026.

## SEC filing metadata
- accession: 0001140361-26-025050
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2026-06-12T18:20:32+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036126025050/0001140361-26-025050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036126025050/ef20076110_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-025050
- JSON: https://secwatch.observer/filing/0001140361-26-025050.json
- Plain text: https://secwatch.observer/filing/0001140361-26-025050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.